nodes	percent_of_prediction	percent_of_DWPC	metapath
Rivaroxaban—CYP3A5—prostate cancer	0.234	0.698	CbGaD
Rivaroxaban—CYP3A4—prostate cancer	0.101	0.302	CbGaD
Rivaroxaban—CYP3A5—Flutamide—prostate cancer	0.0353	0.0878	CbGbCtD
Rivaroxaban—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0316	0.0787	CbGbCtD
Rivaroxaban—CYP3A5—Cabazitaxel—prostate cancer	0.0261	0.065	CbGbCtD
Rivaroxaban—ABCB1—Estramustine—prostate cancer	0.0258	0.0641	CbGbCtD
Rivaroxaban—CYP3A5—Estrone—prostate cancer	0.0255	0.0635	CbGbCtD
Rivaroxaban—ABCB1—Cabazitaxel—prostate cancer	0.017	0.0423	CbGbCtD
Rivaroxaban—CYP3A4—Bicalutamide—prostate cancer	0.0166	0.0413	CbGbCtD
Rivaroxaban—ABCB1—Estrone—prostate cancer	0.0166	0.0413	CbGbCtD
Rivaroxaban—CYP3A4—Estramustine—prostate cancer	0.0155	0.0384	CbGbCtD
Rivaroxaban—ABCB1—Ethinyl Estradiol—prostate cancer	0.0148	0.0368	CbGbCtD
Rivaroxaban—CYP3A5—Estradiol—prostate cancer	0.0147	0.0365	CbGbCtD
Rivaroxaban—CYP3A4—Abiraterone—prostate cancer	0.0138	0.0343	CbGbCtD
Rivaroxaban—CYP3A4—Flutamide—prostate cancer	0.0138	0.0343	CbGbCtD
Rivaroxaban—ABCB1—Conjugated Estrogens—prostate cancer	0.0109	0.027	CbGbCtD
Rivaroxaban—CYP3A4—Cabazitaxel—prostate cancer	0.0102	0.0253	CbGbCtD
Rivaroxaban—CYP3A4—Estrone—prostate cancer	0.00996	0.0248	CbGbCtD
Rivaroxaban—ABCB1—Mitoxantrone—prostate cancer	0.00988	0.0246	CbGbCtD
Rivaroxaban—CYP3A5—Etoposide—prostate cancer	0.00958	0.0238	CbGbCtD
Rivaroxaban—ABCB1—Estradiol—prostate cancer	0.00955	0.0237	CbGbCtD
Rivaroxaban—CYP3A4—Ethinyl Estradiol—prostate cancer	0.00888	0.0221	CbGbCtD
Rivaroxaban—CYP3A5—Docetaxel—prostate cancer	0.00876	0.0218	CbGbCtD
Rivaroxaban—ABCB1—Prednisone—prostate cancer	0.00821	0.0204	CbGbCtD
Rivaroxaban—CYP3A4—Conjugated Estrogens—prostate cancer	0.00651	0.0162	CbGbCtD
Rivaroxaban—ABCB1—Etoposide—prostate cancer	0.00623	0.0155	CbGbCtD
Rivaroxaban—CYP3A4—Mitoxantrone—prostate cancer	0.00592	0.0147	CbGbCtD
Rivaroxaban—CYP3A4—Estradiol—prostate cancer	0.00572	0.0142	CbGbCtD
Rivaroxaban—ABCB1—Docetaxel—prostate cancer	0.0057	0.0142	CbGbCtD
Rivaroxaban—CYP3A4—Prednisone—prostate cancer	0.00492	0.0122	CbGbCtD
Rivaroxaban—ABCB1—Doxorubicin—prostate cancer	0.00425	0.0106	CbGbCtD
Rivaroxaban—CYP3A4—Etoposide—prostate cancer	0.00373	0.00929	CbGbCtD
Rivaroxaban—CYP3A4—Docetaxel—prostate cancer	0.00342	0.0085	CbGbCtD
Rivaroxaban—CYP3A4—Doxorubicin—prostate cancer	0.00255	0.00633	CbGbCtD
Rivaroxaban—F10—prostate gland—prostate cancer	0.00218	0.177	CbGeAlD
Rivaroxaban—CYP2J2—prostate gland—prostate cancer	0.00179	0.145	CbGeAlD
Rivaroxaban—F10—urethra—prostate cancer	0.00146	0.119	CbGeAlD
Rivaroxaban—CYP3A4—urine—prostate cancer	0.00132	0.107	CbGeAlD
Rivaroxaban—F10—testis—prostate cancer	0.000961	0.0781	CbGeAlD
Rivaroxaban—CYP2J2—testis—prostate cancer	0.000788	0.064	CbGeAlD
Rivaroxaban—F10—lymph node—prostate cancer	0.000697	0.0566	CbGeAlD
Rivaroxaban—CYP3A5—prostate gland—prostate cancer	0.000629	0.0511	CbGeAlD
Rivaroxaban—CYP3A5—renal system—prostate cancer	0.000429	0.0348	CbGeAlD
Rivaroxaban—ABCB1—prostate gland—prostate cancer	0.000334	0.0272	CbGeAlD
Rivaroxaban—CYP3A4—renal system—prostate cancer	0.000322	0.0261	CbGeAlD
Rivaroxaban—ABCB1—seminal vesicle—prostate cancer	0.000283	0.023	CbGeAlD
Rivaroxaban—ABCB1—epithelium—prostate cancer	0.000246	0.02	CbGeAlD
Rivaroxaban—ABCB1—renal system—prostate cancer	0.000228	0.0185	CbGeAlD
Rivaroxaban—ABCB1—urethra—prostate cancer	0.000224	0.0182	CbGeAlD
Rivaroxaban—ABCB1—bone marrow—prostate cancer	0.000172	0.014	CbGeAlD
Rivaroxaban—ABCB1—testis—prostate cancer	0.000147	0.012	CbGeAlD
Rivaroxaban—ABCB1—lymph node—prostate cancer	0.000107	0.00867	CbGeAlD
Rivaroxaban—Diarrhoea—Estradiol—prostate cancer	6.11e-05	0.000433	CcSEcCtD
Rivaroxaban—Infestation NOS—Epirubicin—prostate cancer	6.08e-05	0.000431	CcSEcCtD
Rivaroxaban—Infestation—Epirubicin—prostate cancer	6.08e-05	0.000431	CcSEcCtD
Rivaroxaban—Stevens-Johnson syndrome—Epirubicin—prostate cancer	6.03e-05	0.000427	CcSEcCtD
Rivaroxaban—Chest pain—Docetaxel—prostate cancer	6e-05	0.000425	CcSEcCtD
Rivaroxaban—Loss of consciousness—Capecitabine—prostate cancer	6e-05	0.000425	CcSEcCtD
Rivaroxaban—Renal failure—Epirubicin—prostate cancer	5.98e-05	0.000423	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Etoposide—prostate cancer	5.98e-05	0.000423	CcSEcCtD
Rivaroxaban—Asthenia—Mitoxantrone—prostate cancer	5.97e-05	0.000423	CcSEcCtD
Rivaroxaban—Fatigue—Etoposide—prostate cancer	5.97e-05	0.000423	CcSEcCtD
Rivaroxaban—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	5.96e-05	0.000422	CcSEcCtD
Rivaroxaban—Jaundice—Epirubicin—prostate cancer	5.93e-05	0.00042	CcSEcCtD
Rivaroxaban—Pain—Etoposide—prostate cancer	5.92e-05	0.000419	CcSEcCtD
Rivaroxaban—Constipation—Etoposide—prostate cancer	5.92e-05	0.000419	CcSEcCtD
Rivaroxaban—Urinary tract infection—Epirubicin—prostate cancer	5.91e-05	0.000419	CcSEcCtD
Rivaroxaban—Dizziness—Estradiol—prostate cancer	5.91e-05	0.000418	CcSEcCtD
Rivaroxaban—Dry mouth—Docetaxel—prostate cancer	5.87e-05	0.000416	CcSEcCtD
Rivaroxaban—Chest pain—Capecitabine—prostate cancer	5.81e-05	0.000411	CcSEcCtD
Rivaroxaban—Haematuria—Epirubicin—prostate cancer	5.8e-05	0.000411	CcSEcCtD
Rivaroxaban—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	5.77e-05	0.000409	CcSEcCtD
Rivaroxaban—Hepatobiliary disease—Epirubicin—prostate cancer	5.75e-05	0.000407	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Docetaxel—prostate cancer	5.75e-05	0.000407	CcSEcCtD
Rivaroxaban—Oedema—Docetaxel—prostate cancer	5.75e-05	0.000407	CcSEcCtD
Rivaroxaban—Discomfort—Capecitabine—prostate cancer	5.74e-05	0.000406	CcSEcCtD
Rivaroxaban—Epistaxis—Epirubicin—prostate cancer	5.74e-05	0.000406	CcSEcCtD
Rivaroxaban—Infection—Docetaxel—prostate cancer	5.72e-05	0.000405	CcSEcCtD
Rivaroxaban—Sinusitis—Epirubicin—prostate cancer	5.71e-05	0.000404	CcSEcCtD
Rivaroxaban—Feeling abnormal—Etoposide—prostate cancer	5.7e-05	0.000404	CcSEcCtD
Rivaroxaban—Diarrhoea—Mitoxantrone—prostate cancer	5.69e-05	0.000403	CcSEcCtD
Rivaroxaban—Dry mouth—Capecitabine—prostate cancer	5.68e-05	0.000402	CcSEcCtD
Rivaroxaban—Vomiting—Estradiol—prostate cancer	5.68e-05	0.000402	CcSEcCtD
Rivaroxaban—Agranulocytosis—Epirubicin—prostate cancer	5.68e-05	0.000402	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Etoposide—prostate cancer	5.66e-05	0.000401	CcSEcCtD
Rivaroxaban—Shock—Docetaxel—prostate cancer	5.66e-05	0.000401	CcSEcCtD
Rivaroxaban—Nervous system disorder—Docetaxel—prostate cancer	5.64e-05	0.000399	CcSEcCtD
Rivaroxaban—Ill-defined disorder—Prednisone—prostate cancer	5.64e-05	0.000399	CcSEcCtD
Rivaroxaban—Rash—Estradiol—prostate cancer	5.63e-05	0.000399	CcSEcCtD
Rivaroxaban—Infestation—Doxorubicin—prostate cancer	5.63e-05	0.000399	CcSEcCtD
Rivaroxaban—Infestation NOS—Doxorubicin—prostate cancer	5.63e-05	0.000399	CcSEcCtD
Rivaroxaban—Dermatitis—Estradiol—prostate cancer	5.63e-05	0.000398	CcSEcCtD
Rivaroxaban—Anaemia—Prednisone—prostate cancer	5.62e-05	0.000398	CcSEcCtD
Rivaroxaban—Tachycardia—Docetaxel—prostate cancer	5.62e-05	0.000398	CcSEcCtD
Rivaroxaban—Headache—Estradiol—prostate cancer	5.6e-05	0.000396	CcSEcCtD
Rivaroxaban—Skin disorder—Docetaxel—prostate cancer	5.59e-05	0.000396	CcSEcCtD
Rivaroxaban—Stevens-Johnson syndrome—Doxorubicin—prostate cancer	5.58e-05	0.000395	CcSEcCtD
Rivaroxaban—Oedema—Capecitabine—prostate cancer	5.57e-05	0.000394	CcSEcCtD
Rivaroxaban—Angioedema—Prednisone—prostate cancer	5.56e-05	0.000393	CcSEcCtD
Rivaroxaban—Renal failure—Doxorubicin—prostate cancer	5.53e-05	0.000392	CcSEcCtD
Rivaroxaban—Infection—Capecitabine—prostate cancer	5.53e-05	0.000392	CcSEcCtD
Rivaroxaban—Urticaria—Etoposide—prostate cancer	5.5e-05	0.000389	CcSEcCtD
Rivaroxaban—Haemoglobin—Epirubicin—prostate cancer	5.49e-05	0.000389	CcSEcCtD
Rivaroxaban—Jaundice—Doxorubicin—prostate cancer	5.49e-05	0.000389	CcSEcCtD
Rivaroxaban—Malaise—Prednisone—prostate cancer	5.48e-05	0.000388	CcSEcCtD
Rivaroxaban—Shock—Capecitabine—prostate cancer	5.48e-05	0.000388	CcSEcCtD
Rivaroxaban—Abdominal pain—Etoposide—prostate cancer	5.47e-05	0.000387	CcSEcCtD
Rivaroxaban—Urinary tract infection—Doxorubicin—prostate cancer	5.47e-05	0.000387	CcSEcCtD
Rivaroxaban—Nervous system disorder—Capecitabine—prostate cancer	5.46e-05	0.000387	CcSEcCtD
Rivaroxaban—Hepatitis—Epirubicin—prostate cancer	5.46e-05	0.000387	CcSEcCtD
Rivaroxaban—Haemorrhage—Epirubicin—prostate cancer	5.46e-05	0.000387	CcSEcCtD
Rivaroxaban—Syncope—Prednisone—prostate cancer	5.45e-05	0.000386	CcSEcCtD
Rivaroxaban—Tachycardia—Capecitabine—prostate cancer	5.44e-05	0.000385	CcSEcCtD
Rivaroxaban—Skin disorder—Capecitabine—prostate cancer	5.41e-05	0.000383	CcSEcCtD
Rivaroxaban—Urinary tract disorder—Epirubicin—prostate cancer	5.39e-05	0.000382	CcSEcCtD
Rivaroxaban—Hypotension—Docetaxel—prostate cancer	5.38e-05	0.000381	CcSEcCtD
Rivaroxaban—Haematuria—Doxorubicin—prostate cancer	5.37e-05	0.00038	CcSEcCtD
Rivaroxaban—Connective tissue disorder—Epirubicin—prostate cancer	5.37e-05	0.00038	CcSEcCtD
Rivaroxaban—Urethral disorder—Epirubicin—prostate cancer	5.35e-05	0.000379	CcSEcCtD
Rivaroxaban—Loss of consciousness—Prednisone—prostate cancer	5.34e-05	0.000378	CcSEcCtD
Rivaroxaban—Hepatobiliary disease—Doxorubicin—prostate cancer	5.32e-05	0.000377	CcSEcCtD
Rivaroxaban—Epistaxis—Doxorubicin—prostate cancer	5.31e-05	0.000376	CcSEcCtD
Rivaroxaban—Nausea—Estradiol—prostate cancer	5.31e-05	0.000376	CcSEcCtD
Rivaroxaban—Vomiting—Mitoxantrone—prostate cancer	5.29e-05	0.000375	CcSEcCtD
Rivaroxaban—Sinusitis—Doxorubicin—prostate cancer	5.28e-05	0.000374	CcSEcCtD
Rivaroxaban—Agranulocytosis—Doxorubicin—prostate cancer	5.25e-05	0.000372	CcSEcCtD
Rivaroxaban—Rash—Mitoxantrone—prostate cancer	5.25e-05	0.000372	CcSEcCtD
Rivaroxaban—Dermatitis—Mitoxantrone—prostate cancer	5.24e-05	0.000371	CcSEcCtD
Rivaroxaban—Headache—Mitoxantrone—prostate cancer	5.21e-05	0.000369	CcSEcCtD
Rivaroxaban—Hypotension—Capecitabine—prostate cancer	5.21e-05	0.000369	CcSEcCtD
Rivaroxaban—Erythema multiforme—Epirubicin—prostate cancer	5.16e-05	0.000366	CcSEcCtD
Rivaroxaban—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	5.14e-05	0.000364	CcSEcCtD
Rivaroxaban—Dyspnoea—Docetaxel—prostate cancer	5.13e-05	0.000363	CcSEcCtD
Rivaroxaban—Discomfort—Prednisone—prostate cancer	5.11e-05	0.000362	CcSEcCtD
Rivaroxaban—Eye disorder—Epirubicin—prostate cancer	5.1e-05	0.000361	CcSEcCtD
Rivaroxaban—Hypersensitivity—Etoposide—prostate cancer	5.1e-05	0.000361	CcSEcCtD
Rivaroxaban—Haemoglobin—Doxorubicin—prostate cancer	5.08e-05	0.00036	CcSEcCtD
Rivaroxaban—Cardiac disorder—Epirubicin—prostate cancer	5.07e-05	0.000359	CcSEcCtD
Rivaroxaban—Dyspepsia—Docetaxel—prostate cancer	5.06e-05	0.000359	CcSEcCtD
Rivaroxaban—Hepatitis—Doxorubicin—prostate cancer	5.05e-05	0.000358	CcSEcCtD
Rivaroxaban—Haemorrhage—Doxorubicin—prostate cancer	5.05e-05	0.000358	CcSEcCtD
Rivaroxaban—Urinary tract disorder—Doxorubicin—prostate cancer	4.99e-05	0.000353	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Docetaxel—prostate cancer	4.97e-05	0.000352	CcSEcCtD
Rivaroxaban—Asthenia—Etoposide—prostate cancer	4.97e-05	0.000352	CcSEcCtD
Rivaroxaban—Connective tissue disorder—Doxorubicin—prostate cancer	4.97e-05	0.000352	CcSEcCtD
Rivaroxaban—Dyspnoea—Capecitabine—prostate cancer	4.97e-05	0.000352	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Prednisone—prostate cancer	4.96e-05	0.000351	CcSEcCtD
Rivaroxaban—Oedema—Prednisone—prostate cancer	4.96e-05	0.000351	CcSEcCtD
Rivaroxaban—Fatigue—Docetaxel—prostate cancer	4.96e-05	0.000351	CcSEcCtD
Rivaroxaban—Angiopathy—Epirubicin—prostate cancer	4.96e-05	0.000351	CcSEcCtD
Rivaroxaban—Urethral disorder—Doxorubicin—prostate cancer	4.95e-05	0.000351	CcSEcCtD
Rivaroxaban—Nausea—Mitoxantrone—prostate cancer	4.94e-05	0.00035	CcSEcCtD
Rivaroxaban—Immune system disorder—Epirubicin—prostate cancer	4.93e-05	0.000349	CcSEcCtD
Rivaroxaban—Infection—Prednisone—prostate cancer	4.93e-05	0.000349	CcSEcCtD
Rivaroxaban—Mediastinal disorder—Epirubicin—prostate cancer	4.92e-05	0.000349	CcSEcCtD
Rivaroxaban—Constipation—Docetaxel—prostate cancer	4.92e-05	0.000348	CcSEcCtD
Rivaroxaban—Pain—Docetaxel—prostate cancer	4.92e-05	0.000348	CcSEcCtD
Rivaroxaban—Dyspepsia—Capecitabine—prostate cancer	4.9e-05	0.000347	CcSEcCtD
Rivaroxaban—Pruritus—Etoposide—prostate cancer	4.9e-05	0.000347	CcSEcCtD
Rivaroxaban—Shock—Prednisone—prostate cancer	4.88e-05	0.000346	CcSEcCtD
Rivaroxaban—Nervous system disorder—Prednisone—prostate cancer	4.87e-05	0.000345	CcSEcCtD
Rivaroxaban—Tachycardia—Prednisone—prostate cancer	4.84e-05	0.000343	CcSEcCtD
Rivaroxaban—Skin disorder—Prednisone—prostate cancer	4.82e-05	0.000341	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Capecitabine—prostate cancer	4.81e-05	0.00034	CcSEcCtD
Rivaroxaban—Fatigue—Capecitabine—prostate cancer	4.8e-05	0.00034	CcSEcCtD
Rivaroxaban—Erythema multiforme—Doxorubicin—prostate cancer	4.78e-05	0.000338	CcSEcCtD
Rivaroxaban—Pain—Capecitabine—prostate cancer	4.76e-05	0.000337	CcSEcCtD
Rivaroxaban—Constipation—Capecitabine—prostate cancer	4.76e-05	0.000337	CcSEcCtD
Rivaroxaban—Feeling abnormal—Docetaxel—prostate cancer	4.74e-05	0.000336	CcSEcCtD
Rivaroxaban—Diarrhoea—Etoposide—prostate cancer	4.74e-05	0.000335	CcSEcCtD
Rivaroxaban—Eye disorder—Doxorubicin—prostate cancer	4.72e-05	0.000334	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Docetaxel—prostate cancer	4.7e-05	0.000333	CcSEcCtD
Rivaroxaban—Cardiac disorder—Doxorubicin—prostate cancer	4.69e-05	0.000332	CcSEcCtD
Rivaroxaban—Back pain—Epirubicin—prostate cancer	4.6e-05	0.000326	CcSEcCtD
Rivaroxaban—Feeling abnormal—Capecitabine—prostate cancer	4.59e-05	0.000325	CcSEcCtD
Rivaroxaban—Angiopathy—Doxorubicin—prostate cancer	4.59e-05	0.000325	CcSEcCtD
Rivaroxaban—Dizziness—Etoposide—prostate cancer	4.58e-05	0.000324	CcSEcCtD
Rivaroxaban—Muscle spasms—Epirubicin—prostate cancer	4.57e-05	0.000324	CcSEcCtD
Rivaroxaban—Immune system disorder—Doxorubicin—prostate cancer	4.56e-05	0.000323	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Capecitabine—prostate cancer	4.55e-05	0.000323	CcSEcCtD
Rivaroxaban—Mediastinal disorder—Doxorubicin—prostate cancer	4.55e-05	0.000322	CcSEcCtD
Rivaroxaban—Abdominal pain—Docetaxel—prostate cancer	4.55e-05	0.000322	CcSEcCtD
Rivaroxaban—Urticaria—Capecitabine—prostate cancer	4.43e-05	0.000313	CcSEcCtD
Rivaroxaban—Ill-defined disorder—Epirubicin—prostate cancer	4.41e-05	0.000312	CcSEcCtD
Rivaroxaban—Abdominal pain—Capecitabine—prostate cancer	4.4e-05	0.000312	CcSEcCtD
Rivaroxaban—Vomiting—Etoposide—prostate cancer	4.4e-05	0.000312	CcSEcCtD
Rivaroxaban—Anaemia—Epirubicin—prostate cancer	4.39e-05	0.000311	CcSEcCtD
Rivaroxaban—Dyspepsia—Prednisone—prostate cancer	4.37e-05	0.000309	CcSEcCtD
Rivaroxaban—Rash—Etoposide—prostate cancer	4.36e-05	0.000309	CcSEcCtD
Rivaroxaban—Dermatitis—Etoposide—prostate cancer	4.36e-05	0.000309	CcSEcCtD
Rivaroxaban—Headache—Etoposide—prostate cancer	4.34e-05	0.000307	CcSEcCtD
Rivaroxaban—Malaise—Epirubicin—prostate cancer	4.29e-05	0.000304	CcSEcCtD
Rivaroxaban—Fatigue—Prednisone—prostate cancer	4.28e-05	0.000303	CcSEcCtD
Rivaroxaban—Syncope—Epirubicin—prostate cancer	4.26e-05	0.000302	CcSEcCtD
Rivaroxaban—Back pain—Doxorubicin—prostate cancer	4.26e-05	0.000301	CcSEcCtD
Rivaroxaban—Constipation—Prednisone—prostate cancer	4.24e-05	0.0003	CcSEcCtD
Rivaroxaban—Hypersensitivity—Docetaxel—prostate cancer	4.24e-05	0.0003	CcSEcCtD
Rivaroxaban—Muscle spasms—Doxorubicin—prostate cancer	4.23e-05	0.000299	CcSEcCtD
Rivaroxaban—Loss of consciousness—Epirubicin—prostate cancer	4.18e-05	0.000296	CcSEcCtD
Rivaroxaban—Asthenia—Docetaxel—prostate cancer	4.13e-05	0.000292	CcSEcCtD
Rivaroxaban—Nausea—Etoposide—prostate cancer	4.11e-05	0.000291	CcSEcCtD
Rivaroxaban—Hypersensitivity—Capecitabine—prostate cancer	4.1e-05	0.000291	CcSEcCtD
Rivaroxaban—Feeling abnormal—Prednisone—prostate cancer	4.09e-05	0.000289	CcSEcCtD
Rivaroxaban—Ill-defined disorder—Doxorubicin—prostate cancer	4.08e-05	0.000289	CcSEcCtD
Rivaroxaban—Pruritus—Docetaxel—prostate cancer	4.07e-05	0.000288	CcSEcCtD
Rivaroxaban—Anaemia—Doxorubicin—prostate cancer	4.07e-05	0.000288	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Prednisone—prostate cancer	4.06e-05	0.000287	CcSEcCtD
Rivaroxaban—Chest pain—Epirubicin—prostate cancer	4.05e-05	0.000287	CcSEcCtD
Rivaroxaban—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	4.02e-05	0.000285	CcSEcCtD
Rivaroxaban—Discomfort—Epirubicin—prostate cancer	4e-05	0.000283	CcSEcCtD
Rivaroxaban—Asthenia—Capecitabine—prostate cancer	4e-05	0.000283	CcSEcCtD
Rivaroxaban—Malaise—Doxorubicin—prostate cancer	3.97e-05	0.000281	CcSEcCtD
Rivaroxaban—Dry mouth—Epirubicin—prostate cancer	3.96e-05	0.00028	CcSEcCtD
Rivaroxaban—Syncope—Doxorubicin—prostate cancer	3.95e-05	0.000279	CcSEcCtD
Rivaroxaban—Urticaria—Prednisone—prostate cancer	3.94e-05	0.000279	CcSEcCtD
Rivaroxaban—Pruritus—Capecitabine—prostate cancer	3.94e-05	0.000279	CcSEcCtD
Rivaroxaban—Diarrhoea—Docetaxel—prostate cancer	3.94e-05	0.000279	CcSEcCtD
Rivaroxaban—Abdominal pain—Prednisone—prostate cancer	3.92e-05	0.000278	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Epirubicin—prostate cancer	3.88e-05	0.000275	CcSEcCtD
Rivaroxaban—Oedema—Epirubicin—prostate cancer	3.88e-05	0.000275	CcSEcCtD
Rivaroxaban—Loss of consciousness—Doxorubicin—prostate cancer	3.87e-05	0.000274	CcSEcCtD
Rivaroxaban—Infection—Epirubicin—prostate cancer	3.86e-05	0.000273	CcSEcCtD
Rivaroxaban—Shock—Epirubicin—prostate cancer	3.82e-05	0.00027	CcSEcCtD
Rivaroxaban—Diarrhoea—Capecitabine—prostate cancer	3.81e-05	0.00027	CcSEcCtD
Rivaroxaban—Nervous system disorder—Epirubicin—prostate cancer	3.81e-05	0.000269	CcSEcCtD
Rivaroxaban—Dizziness—Docetaxel—prostate cancer	3.8e-05	0.000269	CcSEcCtD
Rivaroxaban—Tachycardia—Epirubicin—prostate cancer	3.79e-05	0.000268	CcSEcCtD
Rivaroxaban—Skin disorder—Epirubicin—prostate cancer	3.77e-05	0.000267	CcSEcCtD
Rivaroxaban—Chest pain—Doxorubicin—prostate cancer	3.75e-05	0.000265	CcSEcCtD
Rivaroxaban—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	3.72e-05	0.000263	CcSEcCtD
Rivaroxaban—Discomfort—Doxorubicin—prostate cancer	3.7e-05	0.000262	CcSEcCtD
Rivaroxaban—Dizziness—Capecitabine—prostate cancer	3.68e-05	0.000261	CcSEcCtD
Rivaroxaban—Dry mouth—Doxorubicin—prostate cancer	3.66e-05	0.000259	CcSEcCtD
Rivaroxaban—Vomiting—Docetaxel—prostate cancer	3.66e-05	0.000259	CcSEcCtD
Rivaroxaban—Hypersensitivity—Prednisone—prostate cancer	3.66e-05	0.000259	CcSEcCtD
Rivaroxaban—Rash—Docetaxel—prostate cancer	3.63e-05	0.000257	CcSEcCtD
Rivaroxaban—Hypotension—Epirubicin—prostate cancer	3.63e-05	0.000257	CcSEcCtD
Rivaroxaban—Dermatitis—Docetaxel—prostate cancer	3.62e-05	0.000257	CcSEcCtD
Rivaroxaban—Headache—Docetaxel—prostate cancer	3.6e-05	0.000255	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Doxorubicin—prostate cancer	3.59e-05	0.000254	CcSEcCtD
Rivaroxaban—Oedema—Doxorubicin—prostate cancer	3.59e-05	0.000254	CcSEcCtD
Rivaroxaban—Infection—Doxorubicin—prostate cancer	3.57e-05	0.000253	CcSEcCtD
Rivaroxaban—Asthenia—Prednisone—prostate cancer	3.56e-05	0.000252	CcSEcCtD
Rivaroxaban—Vomiting—Capecitabine—prostate cancer	3.54e-05	0.000251	CcSEcCtD
Rivaroxaban—Shock—Doxorubicin—prostate cancer	3.53e-05	0.00025	CcSEcCtD
Rivaroxaban—Nervous system disorder—Doxorubicin—prostate cancer	3.52e-05	0.000249	CcSEcCtD
Rivaroxaban—Rash—Capecitabine—prostate cancer	3.51e-05	0.000249	CcSEcCtD
Rivaroxaban—Pruritus—Prednisone—prostate cancer	3.51e-05	0.000249	CcSEcCtD
Rivaroxaban—Dermatitis—Capecitabine—prostate cancer	3.51e-05	0.000248	CcSEcCtD
Rivaroxaban—Tachycardia—Doxorubicin—prostate cancer	3.5e-05	0.000248	CcSEcCtD
Rivaroxaban—Headache—Capecitabine—prostate cancer	3.49e-05	0.000247	CcSEcCtD
Rivaroxaban—Skin disorder—Doxorubicin—prostate cancer	3.49e-05	0.000247	CcSEcCtD
Rivaroxaban—Dyspnoea—Epirubicin—prostate cancer	3.46e-05	0.000245	CcSEcCtD
Rivaroxaban—Nausea—Docetaxel—prostate cancer	3.42e-05	0.000242	CcSEcCtD
Rivaroxaban—Dyspepsia—Epirubicin—prostate cancer	3.42e-05	0.000242	CcSEcCtD
Rivaroxaban—Diarrhoea—Prednisone—prostate cancer	3.39e-05	0.00024	CcSEcCtD
Rivaroxaban—Hypotension—Doxorubicin—prostate cancer	3.36e-05	0.000238	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Epirubicin—prostate cancer	3.35e-05	0.000237	CcSEcCtD
Rivaroxaban—Fatigue—Epirubicin—prostate cancer	3.35e-05	0.000237	CcSEcCtD
Rivaroxaban—Pain—Epirubicin—prostate cancer	3.32e-05	0.000235	CcSEcCtD
Rivaroxaban—Constipation—Epirubicin—prostate cancer	3.32e-05	0.000235	CcSEcCtD
Rivaroxaban—Nausea—Capecitabine—prostate cancer	3.31e-05	0.000234	CcSEcCtD
Rivaroxaban—Dizziness—Prednisone—prostate cancer	3.28e-05	0.000232	CcSEcCtD
Rivaroxaban—Dyspnoea—Doxorubicin—prostate cancer	3.2e-05	0.000227	CcSEcCtD
Rivaroxaban—Feeling abnormal—Epirubicin—prostate cancer	3.2e-05	0.000226	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Epirubicin—prostate cancer	3.17e-05	0.000225	CcSEcCtD
Rivaroxaban—Dyspepsia—Doxorubicin—prostate cancer	3.16e-05	0.000224	CcSEcCtD
Rivaroxaban—Vomiting—Prednisone—prostate cancer	3.15e-05	0.000223	CcSEcCtD
Rivaroxaban—Rash—Prednisone—prostate cancer	3.13e-05	0.000222	CcSEcCtD
Rivaroxaban—Dermatitis—Prednisone—prostate cancer	3.13e-05	0.000221	CcSEcCtD
Rivaroxaban—Headache—Prednisone—prostate cancer	3.11e-05	0.00022	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Doxorubicin—prostate cancer	3.1e-05	0.000219	CcSEcCtD
Rivaroxaban—Fatigue—Doxorubicin—prostate cancer	3.1e-05	0.000219	CcSEcCtD
Rivaroxaban—Urticaria—Epirubicin—prostate cancer	3.08e-05	0.000218	CcSEcCtD
Rivaroxaban—Pain—Doxorubicin—prostate cancer	3.07e-05	0.000217	CcSEcCtD
Rivaroxaban—Constipation—Doxorubicin—prostate cancer	3.07e-05	0.000217	CcSEcCtD
Rivaroxaban—Abdominal pain—Epirubicin—prostate cancer	3.07e-05	0.000217	CcSEcCtD
Rivaroxaban—Feeling abnormal—Doxorubicin—prostate cancer	2.96e-05	0.000209	CcSEcCtD
Rivaroxaban—Nausea—Prednisone—prostate cancer	2.95e-05	0.000209	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Doxorubicin—prostate cancer	2.94e-05	0.000208	CcSEcCtD
Rivaroxaban—Hypersensitivity—Epirubicin—prostate cancer	2.86e-05	0.000202	CcSEcCtD
Rivaroxaban—Urticaria—Doxorubicin—prostate cancer	2.85e-05	0.000202	CcSEcCtD
Rivaroxaban—Abdominal pain—Doxorubicin—prostate cancer	2.84e-05	0.000201	CcSEcCtD
Rivaroxaban—Asthenia—Epirubicin—prostate cancer	2.78e-05	0.000197	CcSEcCtD
Rivaroxaban—Pruritus—Epirubicin—prostate cancer	2.75e-05	0.000194	CcSEcCtD
Rivaroxaban—Diarrhoea—Epirubicin—prostate cancer	2.66e-05	0.000188	CcSEcCtD
Rivaroxaban—Hypersensitivity—Doxorubicin—prostate cancer	2.65e-05	0.000187	CcSEcCtD
Rivaroxaban—Asthenia—Doxorubicin—prostate cancer	2.58e-05	0.000182	CcSEcCtD
Rivaroxaban—Dizziness—Epirubicin—prostate cancer	2.57e-05	0.000182	CcSEcCtD
Rivaroxaban—Pruritus—Doxorubicin—prostate cancer	2.54e-05	0.00018	CcSEcCtD
Rivaroxaban—Vomiting—Epirubicin—prostate cancer	2.47e-05	0.000175	CcSEcCtD
Rivaroxaban—Diarrhoea—Doxorubicin—prostate cancer	2.46e-05	0.000174	CcSEcCtD
Rivaroxaban—Rash—Epirubicin—prostate cancer	2.45e-05	0.000173	CcSEcCtD
Rivaroxaban—Dermatitis—Epirubicin—prostate cancer	2.44e-05	0.000173	CcSEcCtD
Rivaroxaban—Headache—Epirubicin—prostate cancer	2.43e-05	0.000172	CcSEcCtD
Rivaroxaban—Dizziness—Doxorubicin—prostate cancer	2.37e-05	0.000168	CcSEcCtD
Rivaroxaban—Nausea—Epirubicin—prostate cancer	2.31e-05	0.000163	CcSEcCtD
Rivaroxaban—Vomiting—Doxorubicin—prostate cancer	2.28e-05	0.000162	CcSEcCtD
Rivaroxaban—Rash—Doxorubicin—prostate cancer	2.26e-05	0.00016	CcSEcCtD
Rivaroxaban—Dermatitis—Doxorubicin—prostate cancer	2.26e-05	0.00016	CcSEcCtD
Rivaroxaban—Headache—Doxorubicin—prostate cancer	2.25e-05	0.000159	CcSEcCtD
Rivaroxaban—Nausea—Doxorubicin—prostate cancer	2.13e-05	0.000151	CcSEcCtD
Rivaroxaban—CYP3A4—Metabolism—CBR1—prostate cancer	7.9e-06	7.22e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PSAT1—prostate cancer	7.9e-06	7.22e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—TST—prostate cancer	7.9e-06	7.22e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—GRHL1—prostate cancer	7.9e-06	7.22e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—CSAD—prostate cancer	7.9e-06	7.22e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—prostate cancer	7.88e-06	7.2e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—GSTA1—prostate cancer	7.81e-06	7.13e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—prostate cancer	7.8e-06	7.13e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—HSD3B2—prostate cancer	7.72e-06	7.05e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—GSTO1—prostate cancer	7.72e-06	7.05e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—NAT2—prostate cancer	7.72e-06	7.05e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—ACSL4—prostate cancer	7.69e-06	7.02e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—HSD17B3—prostate cancer	7.69e-06	7.02e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—prostate cancer	7.62e-06	6.97e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—prostate cancer	7.61e-06	6.95e-05	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—PIK3CB—prostate cancer	7.53e-06	6.88e-05	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—PTGS2—prostate cancer	7.46e-06	6.82e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—PLCB2—prostate cancer	7.4e-06	6.76e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—CYP2C18—prostate cancer	7.4e-06	6.76e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—LRP2—prostate cancer	7.4e-06	6.76e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—UMPS—prostate cancer	7.37e-06	6.73e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—PHGDH—prostate cancer	7.37e-06	6.73e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—ARG2—prostate cancer	7.37e-06	6.73e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—UGT2B15—prostate cancer	7.35e-06	6.72e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—UGT2B17—prostate cancer	7.35e-06	6.72e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—GRHPR—prostate cancer	7.35e-06	6.72e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—CKMT2—prostate cancer	7.35e-06	6.72e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—NCOA1—prostate cancer	7.33e-06	6.7e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—P4HB—prostate cancer	7.26e-06	6.63e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—prostate cancer	7.25e-06	6.63e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—LDHB—prostate cancer	7.23e-06	6.6e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—CYP3A5—prostate cancer	7.09e-06	6.48e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—SLC22A1—prostate cancer	7.06e-06	6.45e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—prostate cancer	7.05e-06	6.45e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—RXRA—prostate cancer	6.97e-06	6.37e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PGAM2—prostate cancer	6.91e-06	6.31e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—SULT2B1—prostate cancer	6.91e-06	6.31e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—RFK—prostate cancer	6.91e-06	6.31e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—NAGLU—prostate cancer	6.91e-06	6.31e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—AOX1—prostate cancer	6.91e-06	6.31e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—GSTM3—prostate cancer	6.91e-06	6.31e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—MBTPS1—prostate cancer	6.91e-06	6.31e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—SULT2A1—prostate cancer	6.88e-06	6.29e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—prostate cancer	6.87e-06	6.28e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—PDHA1—prostate cancer	6.85e-06	6.26e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—GSTA3—prostate cancer	6.85e-06	6.26e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—UCP3—prostate cancer	6.85e-06	6.26e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—TCN2—prostate cancer	6.85e-06	6.26e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—MED12—prostate cancer	6.77e-06	6.19e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—GNG5—prostate cancer	6.72e-06	6.14e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—AMACR—prostate cancer	6.55e-06	5.99e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—CYP3A43—prostate cancer	6.55e-06	5.99e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—DEGS1—prostate cancer	6.55e-06	5.99e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—SRD5A2—prostate cancer	6.55e-06	5.99e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—NAT1—prostate cancer	6.55e-06	5.99e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—SLC22A3—prostate cancer	6.54e-06	5.97e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—HSD3B1—prostate cancer	6.54e-06	5.97e-05	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—PTEN—prostate cancer	6.5e-06	5.94e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—NCOA3—prostate cancer	6.47e-06	5.91e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—prostate cancer	6.32e-06	5.78e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—prostate cancer	6.31e-06	5.76e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—TBXAS1—prostate cancer	6.27e-06	5.73e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—GSTA4—prostate cancer	6.27e-06	5.73e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—HSD17B1—prostate cancer	6.25e-06	5.71e-05	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—EP300—prostate cancer	6.2e-06	5.67e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—prostate cancer	6.18e-06	5.65e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—HPGDS—prostate cancer	6.17e-06	5.64e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—CYP2C19—prostate cancer	6.13e-06	5.6e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—GSTA2—prostate cancer	6.11e-06	5.58e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—SULT1A1—prostate cancer	6.03e-06	5.51e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—ABCG5—prostate cancer	6.03e-06	5.51e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—ACHE—prostate cancer	5.99e-06	5.47e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—GSTT1—prostate cancer	5.99e-06	5.47e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—CYP2A6—prostate cancer	5.92e-06	5.41e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—GSTA1—prostate cancer	5.89e-06	5.38e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—prostate cancer	5.84e-06	5.34e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—HSD3B2—prostate cancer	5.82e-06	5.32e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—NAT2—prostate cancer	5.82e-06	5.32e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—GSTO1—prostate cancer	5.82e-06	5.32e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—AKR1C3—prostate cancer	5.76e-06	5.26e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—PRKACB—prostate cancer	5.72e-06	5.23e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—CYP17A1—prostate cancer	5.67e-06	5.18e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—PLCB2—prostate cancer	5.58e-06	5.1e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—LRP2—prostate cancer	5.58e-06	5.1e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—CYP2C18—prostate cancer	5.58e-06	5.1e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—HPGD—prostate cancer	5.57e-06	5.09e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—B4GALT4—prostate cancer	5.57e-06	5.09e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—P4HB—prostate cancer	5.48e-06	5.01e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—NCOA2—prostate cancer	5.4e-06	4.93e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—prostate cancer	5.37e-06	4.9e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—SLC22A1—prostate cancer	5.33e-06	4.87e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—PPARA—prostate cancer	5.33e-06	4.87e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—TNFRSF21—prostate cancer	5.24e-06	4.79e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—SULT2A1—prostate cancer	5.19e-06	4.74e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—prostate cancer	5.19e-06	4.74e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—SLC5A5—prostate cancer	5.15e-06	4.71e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—MED12—prostate cancer	5.11e-06	4.67e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—CYP7B1—prostate cancer	5.09e-06	4.66e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—MTAP—prostate cancer	5.09e-06	4.66e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—GNG5—prostate cancer	5.07e-06	4.63e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—CYP2E1—prostate cancer	5.03e-06	4.6e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—NQO1—prostate cancer	4.97e-06	4.55e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—SULT1E1—prostate cancer	4.96e-06	4.54e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—SRD5A1—prostate cancer	4.96e-06	4.54e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—TH—prostate cancer	4.9e-06	4.48e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—NCOA3—prostate cancer	4.88e-06	4.46e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—CYP3A4—prostate cancer	4.85e-06	4.43e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—CYP1B1—prostate cancer	4.77e-06	4.36e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—ACSL4—prostate cancer	4.74e-06	4.33e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—HSD17B3—prostate cancer	4.74e-06	4.33e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—HPGDS—prostate cancer	4.66e-06	4.26e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—CYP2C19—prostate cancer	4.63e-06	4.23e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—GGT1—prostate cancer	4.62e-06	4.22e-05	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—PIK3CA—prostate cancer	4.59e-06	4.19e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—NCOA1—prostate cancer	4.55e-06	4.16e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PHGDH—prostate cancer	4.54e-06	4.15e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—UMPS—prostate cancer	4.54e-06	4.15e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—ARG2—prostate cancer	4.54e-06	4.15e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—ACHE—prostate cancer	4.52e-06	4.13e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—GSTT1—prostate cancer	4.52e-06	4.13e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—CYP19A1—prostate cancer	4.48e-06	4.1e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—CYP2A6—prostate cancer	4.46e-06	4.08e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—LDHB—prostate cancer	4.45e-06	4.07e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—prostate cancer	4.38e-06	4.01e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—CYP3A5—prostate cancer	4.37e-06	3.99e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—AKR1C3—prostate cancer	4.34e-06	3.97e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—RXRA—prostate cancer	4.33e-06	3.95e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—PRKACB—prostate cancer	4.32e-06	3.95e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—CYP17A1—prostate cancer	4.28e-06	3.91e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—CREBBP—prostate cancer	4.23e-06	3.86e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PDHA1—prostate cancer	4.22e-06	3.86e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—TCN2—prostate cancer	4.22e-06	3.86e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—UCP3—prostate cancer	4.22e-06	3.86e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—GSTA3—prostate cancer	4.22e-06	3.86e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—COMT—prostate cancer	4.17e-06	3.81e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—GSTP1—prostate cancer	4.15e-06	3.79e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—ITPR1—prostate cancer	4.08e-06	3.73e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—NCOA2—prostate cancer	4.07e-06	3.72e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—SLC22A3—prostate cancer	4.03e-06	3.68e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—HSD3B1—prostate cancer	4.03e-06	3.68e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—SLC5A5—prostate cancer	3.89e-06	3.55e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—TBXAS1—prostate cancer	3.86e-06	3.53e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—GSTA4—prostate cancer	3.86e-06	3.53e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—TYMS—prostate cancer	3.86e-06	3.52e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—GSTM1—prostate cancer	3.81e-06	3.48e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—CYP2E1—prostate cancer	3.8e-06	3.47e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—GSTA2—prostate cancer	3.76e-06	3.44e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—NQO1—prostate cancer	3.75e-06	3.43e-05	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—AKT1—prostate cancer	3.75e-06	3.43e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—LPL—prostate cancer	3.74e-06	3.42e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—SULT1A1—prostate cancer	3.72e-06	3.4e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—ABCG5—prostate cancer	3.72e-06	3.4e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—TH—prostate cancer	3.7e-06	3.38e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—CYP3A4—prostate cancer	3.66e-06	3.35e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—GSTA1—prostate cancer	3.63e-06	3.32e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—CYP1A1—prostate cancer	3.61e-06	3.3e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—CYP1B1—prostate cancer	3.6e-06	3.29e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—GSTO1—prostate cancer	3.59e-06	3.28e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—HSD3B2—prostate cancer	3.59e-06	3.28e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—NAT2—prostate cancer	3.59e-06	3.28e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—ERCC2—prostate cancer	3.58e-06	3.28e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—GGT1—prostate cancer	3.49e-06	3.19e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PLCB2—prostate cancer	3.44e-06	3.14e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—LRP2—prostate cancer	3.44e-06	3.14e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—CYP2C18—prostate cancer	3.44e-06	3.14e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—NCOA1—prostate cancer	3.43e-06	3.14e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—CYP19A1—prostate cancer	3.38e-06	3.09e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—P4HB—prostate cancer	3.37e-06	3.08e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—MTHFR—prostate cancer	3.37e-06	3.08e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—PPARA—prostate cancer	3.31e-06	3.02e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—SLC22A1—prostate cancer	3.28e-06	3e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—RXRA—prostate cancer	3.27e-06	2.98e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—SULT2A1—prostate cancer	3.2e-06	2.92e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—MED12—prostate cancer	3.15e-06	2.88e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—COMT—prostate cancer	3.15e-06	2.87e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—GSTP1—prostate cancer	3.13e-06	2.86e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—GNG5—prostate cancer	3.12e-06	2.85e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—CAV1—prostate cancer	3.11e-06	2.84e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—ITPR1—prostate cancer	3.08e-06	2.82e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—NCOA3—prostate cancer	3.01e-06	2.75e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—TYMS—prostate cancer	2.91e-06	2.66e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—GSTM1—prostate cancer	2.88e-06	2.63e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—HPGDS—prostate cancer	2.87e-06	2.62e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—CYP2C19—prostate cancer	2.85e-06	2.61e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—PIK3CG—prostate cancer	2.83e-06	2.59e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—LPL—prostate cancer	2.82e-06	2.58e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—GSTT1—prostate cancer	2.78e-06	2.54e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—ACHE—prostate cancer	2.78e-06	2.54e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—CYP2A6—prostate cancer	2.75e-06	2.51e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—CYP1A1—prostate cancer	2.73e-06	2.49e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—ERCC2—prostate cancer	2.7e-06	2.47e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—INS—prostate cancer	2.68e-06	2.45e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—AKR1C3—prostate cancer	2.68e-06	2.45e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PRKACB—prostate cancer	2.66e-06	2.43e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—CYP17A1—prostate cancer	2.63e-06	2.41e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—CREBBP—prostate cancer	2.62e-06	2.4e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—MTHFR—prostate cancer	2.54e-06	2.32e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—NCOA2—prostate cancer	2.51e-06	2.29e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—PPARA—prostate cancer	2.49e-06	2.28e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—PIK3CD—prostate cancer	2.49e-06	2.27e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—SLC5A5—prostate cancer	2.39e-06	2.19e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—NOS3—prostate cancer	2.35e-06	2.15e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—CAV1—prostate cancer	2.35e-06	2.14e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—CYP2E1—prostate cancer	2.34e-06	2.14e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—NQO1—prostate cancer	2.31e-06	2.11e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—TH—prostate cancer	2.28e-06	2.08e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—CYP1B1—prostate cancer	2.22e-06	2.03e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—PIK3CB—prostate cancer	2.17e-06	1.98e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—PTGS2—prostate cancer	2.15e-06	1.96e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—GGT1—prostate cancer	2.15e-06	1.96e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—PIK3CG—prostate cancer	2.14e-06	1.95e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—NCOA1—prostate cancer	2.12e-06	1.93e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—CYP19A1—prostate cancer	2.08e-06	1.91e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—INS—prostate cancer	2.02e-06	1.85e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—RXRA—prostate cancer	2.01e-06	1.84e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—CREBBP—prostate cancer	1.98e-06	1.81e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—COMT—prostate cancer	1.94e-06	1.77e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—GSTP1—prostate cancer	1.93e-06	1.76e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—ITPR1—prostate cancer	1.9e-06	1.73e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—PIK3CD—prostate cancer	1.88e-06	1.72e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—PTEN—prostate cancer	1.87e-06	1.71e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—TYMS—prostate cancer	1.79e-06	1.64e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—EP300—prostate cancer	1.79e-06	1.63e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—NOS3—prostate cancer	1.77e-06	1.62e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—GSTM1—prostate cancer	1.77e-06	1.62e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—LPL—prostate cancer	1.74e-06	1.59e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—CYP1A1—prostate cancer	1.68e-06	1.54e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—ERCC2—prostate cancer	1.67e-06	1.52e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—PIK3CB—prostate cancer	1.64e-06	1.5e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—PTGS2—prostate cancer	1.62e-06	1.48e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—MTHFR—prostate cancer	1.57e-06	1.43e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PPARA—prostate cancer	1.54e-06	1.4e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—CAV1—prostate cancer	1.44e-06	1.32e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—PTEN—prostate cancer	1.41e-06	1.29e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—EP300—prostate cancer	1.35e-06	1.23e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—PIK3CA—prostate cancer	1.32e-06	1.21e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PIK3CG—prostate cancer	1.32e-06	1.2e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—INS—prostate cancer	1.25e-06	1.14e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—CREBBP—prostate cancer	1.22e-06	1.12e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PIK3CD—prostate cancer	1.16e-06	1.06e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—NOS3—prostate cancer	1.09e-06	9.98e-06	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—AKT1—prostate cancer	1.08e-06	9.87e-06	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PIK3CB—prostate cancer	1.01e-06	9.22e-06	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PTGS2—prostate cancer	9.99e-07	9.13e-06	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—PIK3CA—prostate cancer	9.98e-07	9.12e-06	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PTEN—prostate cancer	8.71e-07	7.96e-06	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—EP300—prostate cancer	8.31e-07	7.6e-06	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—AKT1—prostate cancer	8.15e-07	7.45e-06	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PIK3CA—prostate cancer	6.15e-07	5.62e-06	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—AKT1—prostate cancer	5.02e-07	4.59e-06	CbGpPWpGaD
